Clinical trial · Observational
Molecular Classification of Endometrial Cancer: Impact on Adjuvant Treatment Planning.
NCT06584630CI-TRIAL-00080804active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Molecular classification that has been recently incorporated in FIGO classification of endometrial cancer is a new triage tool for the better management of endometrial cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- endometrial cancer patients that underwent molecular classification
Primary outcomes (1)
- measure
- Multidisciplinary Team Board decision change
- timeFrame
- 2 years (study completion)
- description
- MDT decision for adjuvant treatment (Rate of adjuvant treatment change)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histological confirmation of endometrial cancer. * Surgical treatment at our Gynecological - Oncology Unit. Exclusion Criteria: * Refusal to be tested for the molecular classification * Presence of a synchronous neoplasm.
References
Publications (0)
Data not yet available
No reference posted for this study.